The U.S. Food and Drug Administration has approved AbbVie Inc’s
Rinvoq, a JAK kinase inhibitor, to treat moderate-to-severe rheumatoid arthritis in adults for whom methotrexate hasn’t worked, AbbVie announced Friday. The pharmaceutical company said Rinvoq should be available in the U.S. later this month. “Despite the availability of multiple treatment options with varying mechanisms of action, many patients still do not achieve clinical remission or low disease activity – the primary treatment goals for rheumatoid arthritis,” said Roy Fleischmann, a clinical professor at the University of Texas Southwestern Medical Center at Dallas who led one of AbbVie’s clinical trials of Rinvoq. “With this FDA approval, Rinvoq has the potential to help additional people living with RA achieve remission who have not yet reached this goal.” The European Medicines Agency and regulatory authorities in Canada and Japan are still reviewing the drug. Shares of AbbVie were up 2.2% Friday afternoon, though they’ve fallen 30% in the year to date amid investor worry over declining sales of the company’s blockbuster drug Humira. The stock also took a hit in June when the AbbVie said it would be acquiring Botox-maker Allergan Plc in a deal worth around $63 billion. The S&P 500
has gained 15.2% so far this year.
Go to Source